[Prescribing immunosuppressive and immunomodulatory drugs in psoriasis].
Even though systemic immunomodulating or immunosuppressive therapies have shown efficacy in patients with psoriasis, their usage remains restricted to patients with severe, refractory forms of the disease. Indeed, the risk/benefit balance should be cautiously taken into account before prescribing such drugs. Nevertheless, risks inherent to their usage are limited by a careful knowledge of prescription rules and by a monitoring of side effects.
Kemula
Mathilde
M
Service de dermatologie 1, hôpital Saint-Louis, 75475 Paris Cedex 10.
Bachelez
Hervé
H
D000276:Adjuvants, Immunologic / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D012720:Severity of Illness Index
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents